QRG Capital Management Inc. Lowers Position in AbbVie Inc. $ABBV

QRG Capital Management Inc. decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 25.0% in the 3rd quarter, Holdings Channel reports. The firm owned 225,656 shares of the company’s stock after selling 75,094 shares during the period. AbbVie comprises 0.6% of QRG Capital Management Inc.’s investment portfolio, making the stock its 23rd largest holding. QRG Capital Management Inc.’s holdings in AbbVie were worth $52,248,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Marshall & Sullivan Inc. WA bought a new position in shares of AbbVie in the 2nd quarter worth $25,000. Evolution Wealth Management Inc. purchased a new position in AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie in the second quarter valued at $28,000. Financial Gravity Companies Inc. bought a new position in AbbVie in the second quarter valued at $36,000. Finally, Delos Wealth Advisors LLC purchased a new stake in AbbVie during the second quarter valued at about $39,000. 70.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ABBV shares. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a report on Thursday. Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. JPMorgan Chase & Co. increased their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $247.84.

AbbVie Stock Performance

NYSE:ABBV opened at $214.38 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a market cap of $378.89 billion, a PE ratio of 162.41, a price-to-earnings-growth ratio of 0.89 and a beta of 0.36. The business has a 50 day moving average price of $226.80 and a 200-day moving average price of $216.28.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the company earned $3.00 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s payout ratio is currently 496.97%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.